

# Haller J Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6596414/publications.pdf>

Version: 2024-02-01

21  
papers

387  
citations

840776

11  
h-index

794594

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

617  
citing authors

#	ARTICLE	IF	CITATIONS
1	Does health literacy impact technological comfort in cancer patients?. American Journal of Surgery, 2022, 223, 722-728.	1.8	12
2	Implementation and evaluation of a novel subspecialty society fellows robotic surgical course: the SGO minimally invasive academy surgical curriculum. Journal of Gynecologic Oncology, 2021, 32, e26.	2.2	4
3	An enhanced recovery protocol decreases complication rates in high-risk gynecologic oncology patients undergoing non-emergent laparotomy. International Journal of Gynecological Cancer, 2021, 31, 721-726.	2.5	1
4	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. Cancer Medicine, 2021, 10, 709-717.	2.8	14
5	The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice. Gynecologic Oncology, 2020, 156, 284-287.	1.4	17
6	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International Journal of Gynecological Cancer, 2020, 30, 1569-1575.	2.5	10
7	Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm. Gynecologic Oncology, 2020, 159, 773-777.	1.4	11
8	Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting. Gynecologic Oncology Reports, 2019, 29, 123-125.	0.6	3
9	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2019, 153, 381-384.	1.4	28
10	Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2018, 16, 813-824.	3.4	42
11	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer, 2018, 124, 4657-4666.	4.1	22
12	Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy. Gynecologic Oncology, 2018, 151, 282-286.	1.4	42
13	Enhanced Recovery After Surgery in Surgical Specialties. Surgical Clinics of North America, 2018, 98, 1275-1285.	1.5	5
14	Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman. Gynecologic Oncology, 2018, 151, 6-9.	1.4	0
15	Malignant Brenner tumor associated with a germline BRCA2 mutation. Gynecologic Oncology Reports, 2017, 21, 17-19.	0.6	3
16	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecologic Oncology Reports, 2017, 20, 81-86.	0.6	44
17	The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis. Gynecologic Oncology, 2017, 146, 642-646.	1.4	31
18	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget, 2017, 8, 44159-44170.	1.8	41

#	ARTICLE	IF	CITATIONS
19	See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?. Journal of Lower Genital Tract Disease, 2016, 20, 243-246.	1.9	10
20	Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service. Gynecologic Oncology, 2016, 143, 105-108.	1.4	2
21	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2015, 139, 59-62.	1.4	45